CASI Pharmaceuticals, Inc. · OTC:CASIF

CASI Pharmaceuticals — Investor Presentation (September 2021)

24 slides from CASI Pharmaceuticals's investor presentation, September 2021

  1. Slide 1: Corporate Presentation

    Corporate Presentation September 2021

  2. Slide 2: Disclaimer

    Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations and goals. Forward-looking statements are subject to

  3. Slide 3: CASI - Highlights

    CASI - Highlights • EVOMELA® launched in China − Strong growth in sales, with 2020 full-year revenue of $15 million and projected >80% growth in 2021 • CNCT19: CD19 CAR-T Cell Therapy − Granted Breakthrough Therapy Designation and on track for 2021 year end China NDA submission • BI-1206: Checkpoint

  4. Slide 4: Clinical Assets

    Clinical Assets U.S. FDA-Approved Products In-Licensed for Greater China Region In-Licensed CTA Filing & Review Phase 2 Registration NDA Filing & Indication Trial Review EVOMELA Multiple Myeloma Licensed and Commercially Available in China China Developed Innovative Cell Therapy with Co-Commercializ

  5. Slide 5: EVOMELA®

    EVOMELA® 5

  6. Slide 6: EVOMELA® Launched in China

    EVOMELA® Launched in China • Launched in mid-August 2019 – $15 million revenue for 2020, with full- year 2021 revenue guidance of more than 80% growth over 2020 • Only form of injectable melphalan commercially available in China • Used in preparative regimen for autologous stem cell transplant (“ASC

  7. Slide 7: CNCT19

    CNCT19 CD19 CAR-T Therapy Partner: Juventas 7

  8. Slide 8: CNCT19 – Cell Therapy Targeting Clinically Validated CD19 With Significant China Opportunity

    CNCT19 – Cell Therapy Targeting Clinically Validated CD19 With Significant China Opportunity • Targets CD19, B-cell surface protein – validated target for B-cell derived hematological malignancies • There are currently two FDA approved CD19 CAR-Ts: Yescarta® and Kymriah®, with over $1 billion sales

  9. Slide 9: CNCT19 – Juventas Development Timeline

    CNCT19 – Juventas Development Timeline • B-NHL Phase 2 / registration trial currently enrolling in China • B-ALL Phase 2 / registration trial currently enrolling in China • Breakthrough Therapy Designation received in December 2020 from China CDE for B-ALL indication • China NDA submission targeted

  10. Slide 10: BI-1206 Checkpoint Inhibitor Targeting FcγRIIB

    BI-1206 Checkpoint Inhibitor Targeting FcγRIIB Partner: BioInvent 10

  11. Slide 11: BI-1206 – The First Checkpoint Inhibitor Directed Towards Monoclonal Antibody Receptor Interaction

    BI-1206 – The First Checkpoint Inhibitor Directed Towards Monoclonal Antibody Receptor Interaction • First-in-class in hematology – no direct competitors • Fully human monoclonal antibody (“mAb”) that targets FcγRIIB • Acts like a Checkpoint Inhibitor, blocking FcγRIIB interaction to unleash antibod

  12. Slide 12: BI-1206 in NHL – Encouraging Responses From Patients Completing Induction Cycle

    BI-1206 in NHL – Encouraging Responses From Patients Completing Induction Cycle Including Two Enduring CRs • To date, 15 patients enrolled in Part A Responses from 6 of 9 patients completing induction cycle • 9 patients have been evaluated for response, 2 still on treatment 11 10 TO BE VERIFIED − Tw

  13. Slide 13: Phase 1/2a Clinical Trial in Combination with Pembrolizumab

    Phase 1/2a Clinical Trial in Combination with Pembrolizumab • A multicenter, open label, Phase 1/2a study in adults with advanced solid tumors who have relapsed or are refractory to anti-PD-1 or anti-PD-L1 therapy – approximately 60 patients across sites in the U.S. and SWE • High unmet medical need

  14. Slide 14: BI-1206 Upcoming Key Milestones

    BI-1206 Upcoming Key Milestones • Select RP2D, and move to expansion phase (part B) of the study (same patient population) • Include China in global clinical development strategy: implement part B of the study • EoP1 meeting with FDA planned for Q4 2021 − Discuss RP2D and new Phase 2 study design (p

  15. Slide 15: CB-5339 VCP/P97 Inhibitor

    CB-5339 VCP/P97 Inhibitor Partner: Cleave Therapeutics 15

  16. Slide 16: CB-5339 - Clinical Stage Asset Inhibiting Novel Target VCP/p97

    CB-5339 - Clinical Stage Asset Inhibiting Novel Target VCP/p97 Novel target - VCP/p97 Lead Product - CB-5339 • VCP is a AAA ATPase enzyme that • A 2nd generation small molecule inhibitor of VCP/p97 extracts and unfolds proteins, with biochemical potency of 9 nM essential for cancer cell survival • A

  17. Slide 17: VCP/p97 Inhibition Plays a Key Role Regulating Protein Degradation

    VCP/p97 Inhibition Plays a Key Role Regulating Protein Degradation and Drives Cytotoxic Buildup of Proteins in the Endoplasmic Reticulum Endoplasmic Reticulum Endoplasmic Reticulum (ER) Association Degradation (ERAD) Lumen Target for Bortezomib and • Critical to protein homeostasis Aberrant protein

  18. Slide 18: Cleave CB-5339 Phase 1 Study Focused on AML/MDS

    Cleave CB-5339 Phase 1 Study Focused on AML/MDS Open to R/R AML/MDS and Myeloid Malignancies Monotherapy Dose Expansion Combination R/R AML at RP2D R/R AML at RP2D Accelerated Titration 3 + 3 Escalation Monotherapy Dose Expansion Combination Int./Higher Risk MDS Int./Higher Risk MDS • CB-5339 dosed

  19. Slide 19: CID-103

    CID-103 Fully human IgG1 anti-CD38 mAB 19

  20. Slide 20: CID-103: Fully human IgG1 anti-CD38 monoclonal antibody

    CID-103: Fully human IgG1 anti-CD38 monoclonal antibody • Exclusive global rights • Phase 1 trial target initiated in Q1 2021 • Fully human IgG1 anti-CD38 mAb recognizing a unique epitope • No overt infusion related reactions observed • Encouraging preclinical efficacy & safety profile compared to o

  21. Slide 21: CID-103 (TSK011010) – Potential Advantage over Competitor CD38 mAbs

    CID-103 (TSK011010) – Potential Advantage over Competitor CD38 mAbs CID-103 Daratumumab Isatuximab CID-103 Targets a Different CD38 Epitope CID-103 Demonstrates Higher ADCC Activity over Daratumumab and Isatuximab 21 *Sources: AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 3812. TUSK Therapeutics In

  22. Slide 22: Global Senior Management Team

    Global Senior Management Team Wei-Wu He, PhD Larry Zhang, Chairman and CEO President Jim Goldschmidt, PhD, Alex Zukiwski, MD, SVP, Business Chief Medical Officer Development 22

  23. Slide 23: CASI China Management Team

    CASI China Management Team Thomas Zhang, Junping Chen, PhD Cissy Wang, China Commercial GM Medical Director (CASI COO (CASI China) (CASI China) China) Jonathan You, Michael Wu GM of R&D and Mfg. Regulatory Director Site (CASI WUXI) (CASI China) 23

  24. Slide 24: Thank You

    Thank You

CASI Pharmaceuticals — Investor Presentation (September 2021) on 6ix